Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2B, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)
Brief Summary: The purpose of this study was to test if the drug apremilast was safe, if it helped improve psoriasis, and how well the participants tolerated it.


Options:
A: Arm Label: Apremilast; Type: EXPERIMENTAL; Interventions: Drug: Apremilast, Drug: Placebo, Drug: Placebo-Apremilast | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Placebo-Apremilast | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): Apremilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Apremilast, Placebo | Intervention Type: DRUG; Name: Placebo-Apremilast; Assigned to Arm(s): Apremilast, Placebo
B: Arm Label: Apremilast 10mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast 10mg | Arm Label: Apremilast 20mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast 20mg | Arm Label: Apremilast 30 mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast 30 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo/Apremilast 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast 20mg | Arm Label: Placebo/Apremilast 30mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast 30mg | Intervention Type: DRUG; Name: Apremilast 10mg; Assigned to Arm(s): Apremilast 10mg | Intervention Type: DRUG; Name: Apremilast 20mg; Assigned to Arm(s): Apremilast 20mg | Intervention Type: DRUG; Name: Apremilast 30 mg; Assigned to Arm(s): Apremilast 30 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Apremilast 30mg; Assigned to Arm(s): Placebo/Apremilast 30mg | Intervention Type: DRUG; Name: Apremilast 20mg; Assigned to Arm(s): Placebo/Apremilast 20 mg
C: Arm Label: Bimekizumab cohort; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab | Arm Label: Ustekinumab cohort; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab, Other: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Bimekizumab, Other: Placebo | Intervention Type: DRUG; Name: Bimekizumab; Assigned to Arm(s): Bimekizumab cohort, Placebo | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Ustekinumab cohort | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo, Ustekinumab cohort
D: Arm Label: Adalimumab (Part A); Type: ACTIVE_COMPARATOR; Interventions: Biological: adalimumab, Drug: placebo for risankizumab | Arm Label: Risankizumab (Part A); Type: EXPERIMENTAL; Interventions: Drug: risankizumab, Biological: placebo for adalimumab | Intervention Type: DRUG; Name: risankizumab; Assigned to Arm(s): Risankizumab (Part A) | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab (Part A) | Intervention Type: DRUG; Name: placebo for risankizumab; Assigned to Arm(s): Adalimumab (Part A) | Intervention Type: BIOLOGICAL; Name: placebo for adalimumab; Assigned to Arm(s): Risankizumab (Part A)

Answer: B